Five-Year Longitudinal Assessment (2008 to 2012) of E-101 Solution Activity against Clinical Target and Antimicrobial-Resistant Pathogens

被引：1

作者：

Denys, Gerald A. ^{[1
]}

Pillar, Chris M. ^{[2
]}

Sahm, Daniel F. ^{[2
]}

O'Hanley, Peter ^{[3
]}

Stephens, Jackson T., Jr. ^{[3
]}

机构：

[1] Indiana Univ Sch Med, Indianapolis, IN 46202 USA

[2] Eurofins Medinet, Chantilly, VA USA

[3] Exoxemis Inc, Little Rock, AR USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2014年 / 58卷 / 08期

关键词：

NO ESKAPE; IN-VITRO; MYELOPEROXIDASE; BACTERIA; BINDING;

D O I：

10.1128/AAC.03020-14

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

This study summarizes the topical E-101 solution susceptibility testing results for 760 Gram-positive and Gram-negative target pathogens collected from 75 U.S. sites between 2008 and 2012 and 103 ESKAPE pathogens. E-101 solution maintained potent activity against all bacterial species studied for each year tested, with MICs ranging from <0.008 to 0.25 mu g porcine myeloperoxidase (pMPO)/ml. These results confirm that E-101 solution retains its potent broad-spectrum activity against U.S. clinical isolates and organisms with challenging resistance phenotypes.

引用

页码：4911 / 4914

页数：4

共 18 条

[1] Reduced-oxidized difference spectral analysis and chemiluminescence-based Scatchard analysis demonstrate selective binding of myeloperoxidase to microbes
Allen, Robert C.
Stephens, Jackson T., Jr.
[J]. LUMINESCENCE, 2011, 26 (03) : 208 - 213
[2] Myeloperoxidase Selectively Binds and Selectively Kills Microbes
Allen, Robert C.
Stephens, Jackson T., Jr.
[J]. INFECTION AND IMMUNITY, 2011, 79 (01) : 474 - 485
[3] Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
Boucher, Helen W.
Talbot, George H.
Bradley, John S.
Edwards, John E., Jr.
Gilbert, David
Rice, Louis B.
Scheld, Michael
Spellberg, Brad
Bartlett, John
[J]. CLINICAL INFECTIOUS DISEASES, 2009, 48 (01) : 1 - 12
[4] Binding of myeloperoxidase to bacteria: Effect on hydroxyl radical formation and susceptibility to oxidant-mediated killing
Britigan, BE
Ratcliffe, HR
Buettner, GR
Rosen, GM
[J]. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 1996, 1290 (03): : 231 - 240
[5] Clinical and Laboratory Standards Institute, 2012, M07A9 CLIN LAB STAND
[6] Clinical and Laboratory Standards Institute, 2013, M100S23 CLIN LAB STA
[7] Development and Evaluation of a Real-Time PCR Assay for Detection of Klebsiella pneumoniae Carbapenemase Genes
Cole, Justin M.
Schuetz, Audrey N.
Hill, Charles E.
Nolte, Frederick S.
[J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2009, 47 (02) : 322 - 326
[8] In Vitro and In Vivo Activities of E-101 Solution against Acinetobacter baumannii Isolates from US Military Personnel
Denys, G. A.
Davis, J. C.
O'Hanley, P. D.
Stephens, J. T., Jr.
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (07) : 3603 - 3608
[9] Denys GA, 2014, J ANTIMICROB PHOTON, V129, P278
[10] In vitro antibacterial activity of E-101 Solution, a novel myeloperoxidase-mediated antimicrobial, against Gram-positive and Gram-negative pathogens
Denys, Gerald A.
Grover, Parveen
O'Hanley, Peter
Stephens, Jackson T., Jr.
[J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2011, 66 (02) : 335 - 342

← 1 2 →